Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 161 to 170 of 542 total matches.
Treatment of COVID-19 in High-Risk Outpatients (online only)
The Medical Letter on Drugs and Therapeutics • Jan 28, 2022 (Issue 1643)
., amiodarone, midazolam)
Sotrovimab
• Dosage: 500 mg IV x 1 dose
• Begin ≤10 days after symptom onset ...
View the Treatment of COVID-19 in High-Risk Outpatients Chart
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
excluded from the analysis.1
Qsymia, a fixed-dose combination of phentermine and
an extended-release ...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight...
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
▶ Recommended for prevention of AMS in
adults and children
$3.00
Dexamethasone – generic 0.5, 0.75, 1, 1.5, 2 ...
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
of COVID-19 in
hospitalized patients since 2020.1 Now, the FDA has
approved remdesivir for treatment ...
The IV antiviral drug remdesivir (Veklury – Gilead)
has been available for treatment of COVID-19 in
hospitalized patients since 2020. Now, the FDA has
approved remdesivir for treatment of mild to moderate
COVID-19 in outpatients ≥12 years old who weigh
≥40 kg and are at high risk for progression to severe
disease, including hospitalization or death; they
also issued an Emergency Use Authorization (EUA)
allowing its use in any other high-risk outpatient who
weighs ≥3.5 kg.
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated ...
The FDA has approved elacestrant (Orserdu –
Stemline), an oral estrogen receptor antagonist, for
treatment of estrogen receptor (ER)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated advanced or
metastatic breast cancer in postmenopausal women
or men who had disease progression following
endocrine therapy. Elacestrant is the first oral selective
estrogen receptor degrader (SERD) to be approved
for treatment of breast cancer; the injectable SERD
fulvestrant (Faslodex, and generics) was approved
more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40 doi:10.58347/tml.2023.1671d | Show Introduction Hide Introduction
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
43,548 subjects ≥16 years old were randomized 1:1
to receive 30 mcg of the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
.1 Dupilumab is
also approved for several other indications, including
add-on treatment in patients ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
COVID-19 Update: Metformin to Prevent Long Covid?
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
ward
than in those who did not (43.1% and 27.5% vs 5.7%).
It was most prevalent in adult females.1 ...
Results from a double-blind trial suggest that off-label
use of the oral antihyperglycemic drug metformin
in patients with COVID-19 may decrease the risk
of post-acute sequelae of SARS-CoV-2 infection
("long COVID").
Med Lett Drugs Ther. 2023 May 29;65(1677):87-8 doi:10.58347/tml.2023.1677e | Show Introduction Hide Introduction